M Murillo Izquierdo

Background Idiopathic pulmonary fibrosis (IPF) is a specific type of chronic fibrosing interstitial pneumonia. Nintedanib is a tyrosine kinase inhibitor which has been approved for the clinical treatment of IPF in adults. Material and methods An observational retrospective study was conducted in patients receiving treatment with nintedanib from May 2015 to September 2016. Measured variables were: age, sex and smoking habits.

Background Fampridine is indicated to improve walking in adult patients with multiple sclerosis (MS) and an expanded disability status scale (EDSS) score of 4–7. In order to evaluate continuation of treatment, there should be at least an improvement of 20% in their timed 25 foot walk test (T25FW) after taking the drug for 2 weeks.

Background The ?-9-tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray (Sativex) is a standardised cannabinoid based medicine for add on treatment of resistant multiple sclerosis (MS) induced spasticity. Purpose To evaluate the use of oromucosal spray Sativex in terms of efficacy for symptoms and functional impairment associated with resistant MS induced spasticity and safety according to type of MS.